Some of the most expensive drugs currently in use are gene therapies to treat specific diseases, and their high cost limits ...

FRIDAY, Oct. 31, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax ...

Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments.

The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may ...

The U.S. Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

Eva-Maria Hempe, NVIDIA, says bio/pharma must centralize AI strategy, tackle silos, prioritize process integrity, and balance quick wins with long-term drug design goals.

This recall affects America’s most prescribed drug. It’s the latest in a series of manufacturing issues that have come to ...

The company will begin its domestic investment by starting construction on a $3 billion pharmaceutical manufacturing site in ...

Ajinomoto Bio-Pharma Services and Olon S.p.A. have entered into a strategic partnership to deliver drug substance manufacturing services.

But last week, those words took on the force of law. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit against ...

The U.S. Food and Drug Administration announced it will relax certain rules for approving low-cost versions of some high-priced medications to reduce costs.

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative ...